Swaziland Develops Key Performance Indicators to Improve Warehouse Management

In 2014, SIAPS supported the Ministry of Health (MOH), Central Medical Stores (CMS), and Swaziland Health Laboratory Services (SHLS) by conducting a workshop to build capacity and improve performance of staff that works in warehouse operations. The Imperial Health Services warehouse was used as a model to showcase warehousing best practices.

Implementing an TB/HIV Active Surveillance System in Swaziland

SIAPS supported the Swaziland Ministry of Health (MOH) in mobilizing key stakeholders from the Swaziland National AIDS Program and the National Tuberculosis Control Program to introduce and implement an active surveillance system for patients on ARVs and anti-TB treatment. SIAPS provided technical assistance to MOH’s National Pharmacovigilance Unit (NPVU) to develop the protocol and tools to implement the system, as well as to develop a system for recruiting patients at the HIV and TB sites.

Rapport de quantification des produits de la santé reproductive, maternelle, néonatale, et infantile pour la période de janvier 2016 à décembre 2020

L’accès à des médicaments appropriés est vital pour parvenir aux objectifs mondiaux en matière de santé, en particulier les produits destinés pour la santé de la femme et de l’enfant. Un élément majeur de l’accès est de garantir la disponibilité des produits. Pour cela, la quantification des besoins est indispensable. La présente activité a apporté un soutien au Ministère de la Santé et de l’Hygiène Publique (MSHP) pour la quantification des besoins en médicaments pour la santé reproductive, maternelle, néonatale, et infantile (SRMNI). C’est ainsi que la Direction de la Pharmacie et du Médicament (DPM), à travers l’appui technique et financier de SIAPS, a organisé un atelier de quantification des besoins de ces produits. Avec la participation de tous les principaux intervenants dans le but de produire des besoins prévisionnels, un plan d’approvisionnement pour la période de 2016 à 2020 était préparé.

Rapport de quantification des intrants de lutte contre la maladie à virus Ebola: Période janvier 2016 à décembre 2018

Pour mieux coordonner les activités de lutte contre la maladie à virus Ebola (MVE), l’engagement de l’État Malien s’est traduit par l’élaboration du plan de contingence et la création d’un Centre Opérationnel Urgence. Dans le souci rendre disponible des prévisions faites de façon consensuelle et avec l’implication des parties prenantes, un exercice de quantification a été mené avec l’assistance technique et  financement de SIAPS. Il permettra de mobiliser et obtenir des ressources financières pour l’achat des intrants de lutte contre la MVE.

Rapport de l’enquête sur la vérification de l’utilisation finale des produits de lutte contre le paludisme au Mali, Août 9-31, 2016

La présente édition de l’enquête sur la vérification de l’utilisation finale (EUV) des produits de lutte contre le paludisme a été réalisée entre Août 9-31, 2016 sous la direction du Programme National de Lutte contre le Paludisme (PNLP) dans les régions du sud et centre du Mali. L’objectif de l’étude est de contribuer à améliorer la disponibilité, la gestion, et l’utilisation des médicaments et autres intrants antipaludiques dans les structures sanitaires publiques et parapubliques du Mali.

SIAPS Activity and Product Status Report: Year 6, Quarter 2

This report presents highlights of SIAPS’ activities organized both by intermediate result area, representing multiple countries where we work, as well as by our global, regional, and country portfolios for the January through March 2017 period.

Report on Routine Supportive Supervision Visits to Health Facilities in the Hhohho and Lubombo Regions, Swaziland

Since October 2015, SIAPS has been supporting hospitals, health centers, and high volume clinics at the request of regional implementing partners in the Hhohho and Lubombo regions. This report documents the support that facilities have received, progress made, and recommendations for future support.

Evaluation of SIAPS Supportive Supervision and Mentorship Activities

This report presents highlights of SIAPS’ work to capacitate health workers on proper pharmaceutical service delivery and stock management over a four-year period (2012 to 2015). SIAPS did a baseline assessment at health facilities (HF) in 2012, and then from 2013 to 2015, its technical advisors provided assistance to address the identified performance gaps. The objectives of this evaluation were to document results achieved from implementing mentorship and supportive supervision (SS) visits in supply chain management and pharmaceutical services; and present lessons learned from the implementation of these visits.

The Economic Cost of Non-Adherence to TB Medicines Resulting from Stock-Outs and Loss to Follow-Up in the Philippines

A key element of successful tuberculosis (TB) control programs is adherence to treatment. Non-adherence results in increased length and severity of illness, death, disease transmission, and drug resistance. The purpose of this study was to estimate the morbidity and mortality impact and economic costs of non-adherence to TB medicines resulting from treatment interruption due to stock-outs or loss to follow-up (LTFU).

The Economic Cost of Non-adherence to TB Medicines Resulting from Stock-outs and Loss to Follow-up in Kenya – Research Summary

One of the key elements of successful tuberculosis (TB) control programs is adherence to treatment, which is a cornerstone of most international and national policies and guidelines. Non-adherence results in increased length and severity of illness, death, disease transmission, and drug resistance. Treatment interruption is often due to patient-related factors—classed as loss to follow-up (LTFU)—but can also be a result of provider issues, such as stock-outs of medicines. The purpose of this study was to estimate the morbidity, mortality, and economic impact of TB treatment interruption due to stock-outs and LTFU. The results are expected to help promote the benefits of ensuring the availability of good quality medicines and of undertaking interventions to reduce LTFU.

For the full report, please follow this link.